Demand for Autoimmune Disease Diagnostic Products Remains High in North America

Around 3% of the people in the U.S. are affected by autoimmune diseases every year, according to Johns Hopkins University. In such diseases, the immune system malfunctions and starts attacking the healthy cells instead of pathogens. Some of the common autoimmune diseases are celiac disease, lupus, myasthenia gravis, rheumatoid arthritis, Grave’s disease, type 1 diabetes, Guillain–Barre syndrome, multiple sclerosis, and Sjögren syndrome. These diseases are often not treatable, therefore have significant long-term adverse effects on people’s health.

Receive Sample Pages of this Report: https://www.psmarketresearch.com/market-analysis/autoimmune-disease-diagnostics-market-report/report-sample

In addition to themselves being a cause of morbidity, certain autoimmune diseases are also associated with cancer. Thus, with the increasing awareness about these diseases and their effective management, the autoimmune disease diagnostics market will witness an 8.5% CAGR during the forecast period (2020–2030). According to P&S Intelligence, at this rate, the revenue generated by biotech and medical device companies from the sale of diagnostic products will rise to $10,012.9 million by 2030 from $4,086.2 million in 2019.

The test type segment of the autoimmune disease diagnostics market is divided into inflammatory marker, routine laboratory, human leukocyte antigen (HLA), autoantibodies and immunology, flow cytometry, cytokine, and others. Among these, the routine laboratory category held the largest share during 2014–2019 (historical period), because routine laboratory tests, including serum and blood tests, are the first in the series of many used to diagnose an autoimmune condition. Often, the blood needs to be scanned more than once for anomalies, which leads to the highest volume of such tests.

Make an Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=autoimmune-disease-diagnostics-market-report

Moreover, a new biomarker for the detection of myasthenia gravis was identified by the University of Alberta in August 2019. Apart from disease diagnosis, the university claims that the biomarker can be used to study the prognosis of the disease and engineer personalized treatments. Thus, owing to such extensive research and development (R&D), North America has been the most-productive autoimmune disease diagnostics market till now. In 2019, 24 million U.S. citizens had autoimmune diseases, while 8 million tested positive for auto-antibodies, which means they will probably contract an autoimmune disease.

Therefore, with the increasing prevalence of such long-term diseases, which not only affect the quality of people’s lives adversely but can also lead to more-serious diseases, such as cancer, the demand for the various consumables, assay kits, and instruments used for their diagnoses will rise.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com

This release was published on openPR.